587 completed, 300 unknown, 74 terminated, 47 recruiting. 1106 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 1106 | Completed 587, Unknown 300, Terminated 74, Recruiting 47, Withdrawn 47, Not yet recruiting 27, Active not recruiting 18, Enrolling by invitation 5, Suspended 1 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus | Phase 4 | Not yet recruiting | Eunice Dube | 2140 | 2027-01-30 | 2026-07-30 |
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants Bepirovirsen - Hepatitis B | Phase 4 | Not yet recruiting | GlaxoSmithKline | 303 | 2026-12-03 | 2026-11-02 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) CE1226 - Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency | Phase 4 | Recruiting | CSL Behring | 270 | 2026-09-29 | 2026-10-16 |
| Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine N-Acetylcysteine (NAC) Treatment - Sepsis, Acute Infection | Phase 4 | Recruiting | Theis S. Itenov | 360 | 2026-09-07 | 2026-09-16 |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) Mazdutide, Placebo (Normal Saline), Lifestyle Optimization - Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis | Phase 4 | Recruiting | West China Hospital | 60 | 2026-09-01 | 2026-09-23 |
| Daridorexant for Sleep Disturbance in Adults With Liver Cirrhosis Daridorexant, Placebo - Liver Cirrhosis, Sleep Disturbance | Phase 4 | Not yet recruiting | Wang Fengmei | 180 | 2026-09-01 | 2026-10-16 |
| A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab - Liver Cancer | Phase 4 | Not yet recruiting | Zhai Wenlong | 40 | 2026-08-30 | 2026-08-27 |
| SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma Stereotactic Body Radiation Therapy (SBRT), QL1706 - HCC - Hepatocellular Carcinoma | Phase 4 | Not yet recruiting | Hebei Medical University Fourth Hospital | 36 | 2026-07-01 | 2026-06-25 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis Apixaban, Carvedilol, Placebo - Cirrhosis, Esophageal and Gastric Varices | Phase 4 | Recruiting | Asian Institute Of Medical Sciences | 220 | 2026-04-01 | 2026-04-09 |
| Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant Atezolizumab, Bevacizumab, Y^90 Radioembolization - Hepatocellular Carcinoma | Phase 4 | Recruiting | Icahn School of Medicine at Mount Sinai | 40 | 2026-03-26 | 2026-07-28 |
| Prediction of Complications in Hepatic Tumors [99mTc] Tc-GSA SPECT/CT - Hepatic Tumors | Phase 4 | Not yet recruiting | Copenhagen University Hospital, Rigshospitalet | 192 | 2026-03-01 | 2026-01-22 |
| A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations Anaprazole Sodium enteric-coated tablet - Hepatic Insufficiency, Renal Insufficiency | Phase 4 | Not yet recruiting | Xuanzhu Biopharmaceutical Co., Ltd. | 60 | 2026-01-30 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 80 | 2026-01-11 | 2026-01-16 |
| Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B Entecavir, Entecavir + Pegylated interferon α-2b - Hepatitis B Virus Infection, Children | Phase 4 | Not yet recruiting | Qing-Lei Zeng | 60 | 2026-01-11 | 2026-01-16 |
| Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach Tenofovir Alafenamide (TAF), Community-Based Support, Simplified WHO 2024 Criteria - Chronic Hepatitis B, Hepatitis B Virus Infection | Phase 4 | Not yet recruiting | The Task Force for Global Health | 6000 | 2026-01-01 | 2025-12-02 |
| Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B Peginterferon alfa-2b Injection - HBV, Chronic Hepatitis B Virus | Phase 4 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 113 | 2026-01-01 | 2025-11-17 |
| Comparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver Entecavir - Hepatitis B | Phase 4 | Recruiting | Bangladesh Medical University | 48 | 2026-01-01 | 2026-09-11 |
Showing 20 of 1106. Sign in to see all of them.
Hepatitis B, Chronic (190) · Hepatitis C (184) · Hepatitis B (174) · Hepatitis C, Chronic (144) · Carcinoma, Hepatocellular (105) · Liver Cirrhosis (88) · Non-alcoholic Fatty Liver Disease (80) · Fibrosis (63) · Liver Neoplasms (39) · Diabetes Mellitus, Type 2 (37) · Fatty Liver (37) · Hypertension, Portal (37) · Hepatic Encephalopathy (35) · HIV Infections (32)
Digestive System Diseases (1102) · Infections (674) · Virus Diseases (660) · Hepatitis (657) · Hepatitis, Viral, Human (652) · Blood-Borne Infections (632) · Communicable Diseases (631) · Pathological Conditions, Signs and Symptoms (558) · Pathologic Processes (536) · Disease Attributes (370) · RNA Virus Infections (356) · Chronic Disease (350) · Hepatitis, Chronic (337) · DNA Virus Infections (335)
Ribavirin (140) · peginterferon alfa-2a (126) · entecavir (74) · Tenofovir (56) · Sofosbuvir (42) · Lamivudine (36) · peginterferon alfa-2b (34) · Telbivudine (27) · sofosbuvir-velpatasvir drug combination (26) · Hepatitis B Vaccines (24) · adefovir (23) · adefovir dipivoxil (23) · Hepatitis A Vaccines (22) · tenofovir alafenamide (21) · Pioglitazone (20)
GlaxoSmithKline (47) · Hoffmann-La Roche (44) · National Taiwan University Hospital (25) · Sun Yat-sen University (21) · Merck Sharp & Dohme LLC (15) · Taipei Veterans General Hospital, Taiwan (15) · Third Affiliated Hospital, Sun Yat-Sen University (15) · Yonsei University (13) · Kaohsiung Medical University Chung-Ho Memorial Hospital (11) · Kirby Institute (11) · Massachusetts General Hospital (11) · Nanfang Hospital, Southern Medical University (11) · Ain Shams University (9) · Novartis Pharmaceuticals (9) · Asan Medical Center (8)
China (208) · United States (207) · South Korea (88) · Taiwan (81) · Germany (52) · Spain (51) · Canada (48) · Egypt (42) · Belgium (31) · India (30) · Australia (28) · Italy (28) · Brazil (26) · United Kingdom (26) · Netherlands (23)
Chen-Hua Liu, MD (9) · Jia-Horng Kao, MD, PhD (6) · Shih-Jer Hsu, MD (6) · Cheng-Chao Liang, MD (5) · Jun Cheng, M.D. (5) · Ming-Lung Yu, MD, PhD (5) · Raymond T Chung, MD (5) · Shiyao Chen, Professor (5) · Arnulf Ferlitsch, MD (4)
PMID 32710245, PMID 37467180, PMID 24915612, PMID 28404091, PMID 28404092, PMID 15470215, PMID 19187608, PMID 21182232, PMID 22436845, PMID 23046671, PMID 23518903, PMID 25348661, PMID 28427875, PMID 29405329, PMID 11981766, PMID 12049862, PMID 12091661, PMID 12540794, PMID 15014185, PMID 19052126, PMID 19208350, PMID 19729084, PMID 20009522, PMID 20049753, PMID 21366801, PMID 22045673, PMID 22508412, PMID 22777097, PMID 23732904, PMID 24508042, PMID 24954675, PMID 25190434, PMID 26026936, PMID 26190091, PMID 26453773, PMID 26867206, PMID 29696665, PMID 29960156, PMID 30237305, PMID 30552056, PMID 30576085, PMID 30689258, PMID 33293204, PMID 33460002, PMID 34843068, PMID 35599306, PMID 36262060, PMID 37096802, PMID 39373164, PMID 39641307
2005 (5), 2014 (4), 2019 (4), 2009 (3), 2015 (3), 2004 (2), 2008 (2), 2016 (2), 2018 (2), 2017 (1), 2023 (1), 2025 (1), K23DK062116 (1), K23DK082621 (1), K23DK115827 (1)